Compare Stocks: INO, MRNA, TARA, and WHWK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INO Inovio Pharmaceuticals	$1.09 +21.1%	$1.03	$0.56 ▼ $2.98	$93.07M	1.52	5.18 million shs	12.17 million shs
MRNA Moderna	$63.32 -0.5%	$61.70	$22.28 ▼ $85.60	$25.41B	0.91	5.41 million shs	4.69 million shs
TARA Protara Therapeutics	$3.97 +0.8%	$4.02	$2.97 ▼ $7.82	$232.84M	1.5	394,483 shs	333,029 shs
WHWK Whitehawk Therapeutics	$4.46 -4.7%	$4.14	$1.57 ▼ $5.49	$266.80M	0.76	462,817 shs	260,299 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INO Inovio Pharmaceuticals	+21.10%	+63.17%	-6.84%	-16.15%	-35.88%
MRNA Moderna	-0.52%	+7.01%	-7.26%	+29.12%	+135.48%
TARA Protara Therapeutics	+0.76%	-3.64%	-3.64%	-22.16%	+21.78%
WHWK Whitehawk Therapeutics	-4.70%	-6.30%	+15.84%	-5.11%	+160.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INO Inovio Pharmaceuticals	$1.09 +21.1%	$1.03	$0.56 ▼ $2.98	$93.07M	1.52	5.18 million shs	12.17 million shs
MRNA Moderna	$63.32 -0.5%	$61.70	$22.28 ▼ $85.60	$25.41B	0.91	5.41 million shs	4.69 million shs
TARA Protara Therapeutics	$3.97 +0.8%	$4.02	$2.97 ▼ $7.82	$232.84M	1.5	394,483 shs	333,029 shs
WHWK Whitehawk Therapeutics	$4.46 -4.7%	$4.14	$1.57 ▼ $5.49	$266.80M	0.76	462,817 shs	260,299 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INO Inovio Pharmaceuticals	+21.10%	+63.17%	-6.84%	-16.15%	-35.88%
MRNA Moderna	-0.52%	+7.01%	-7.26%	+29.12%	+135.48%
TARA Protara Therapeutics	+0.76%	-3.64%	-3.64%	-22.16%	+21.78%
WHWK Whitehawk Therapeutics	-4.70%	-6.30%	+15.84%	-5.11%	+160.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	190.52% Upside
MRNA Moderna	1.88	Reduce	$42.13	-33.46% Downside
TARA Protara Therapeutics	2.75	Moderate Buy	$26.25	561.21% Upside
WHWK Whitehawk Therapeutics	2.63	Moderate Buy	$8.20	83.86% Upside

Current Analyst Ratings Breakdown

Latest INO, MRNA, TARA, and WHWK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/13/2026	INO Inovio Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Positive	$1.80 ➝ $3.00
8/12/2026	INO Inovio Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/3/2026	MRNA Moderna	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/3/2026	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$41.00 ➝ $60.00
8/3/2026	INO Inovio Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$4.00
7/29/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	MRNA Moderna	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$49.00 ➝ $67.00
7/20/2026	MRNA Moderna	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$25.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INO Inovio Pharmaceuticals	$60K	1,878.43	N/A	N/A	$0.04 per share	27.25
MRNA Moderna	$1.94B	13.00	N/A	N/A	$16.93 per share	3.74
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$2.73 per share	N/A
WHWK Whitehawk Therapeutics	$7.14M	35.61	N/A	N/A	$3.21 per share	1.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INO Inovio Pharmaceuticals	-$84.95M	-$1.45	N/A	N/A	N/A	N/A	-669.94%	-73.97%	N/A
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	N/A
TARA Protara Therapeutics	-$57.44M	-$1.34	N/A	N/A	N/A	N/A	-41.72%	-38.78%	N/A
WHWK Whitehawk Therapeutics	-$20.60M	-$1.12	N/A	N/A	N/A	N/A	-53.89%	-49.97%	N/A

Latest INO, MRNA, TARA, and WHWK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A
8/11/2026	Q2 2026	TARA Protara Therapeutics	-$0.3257	-$0.36	-$0.0343	-$0.36	N/A	N/A
8/6/2026	Q2 2026	WHWK Whitehawk Therapeutics	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INO Inovio Pharmaceuticals	N/A	1.00	1.04
MRNA Moderna	0.09	2.29	2.18
TARA Protara Therapeutics	N/A	10.97	15.69
WHWK Whitehawk Therapeutics	N/A	17.38	11.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INO Inovio Pharmaceuticals	26.79%
MRNA Moderna	75.33%
TARA Protara Therapeutics	38.13%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
INO Inovio Pharmaceuticals	1.70%
MRNA Moderna	10.80%
TARA Protara Therapeutics	7.60%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INO Inovio Pharmaceuticals	320	103.40 million	80.87 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
TARA Protara Therapeutics	30	59.10 million	54.60 million	Optionable
WHWK Whitehawk Therapeutics	21	57.01 million	28.56 million	N/A

INO, MRNA, TARA, and WHWK Headlines

Recent News About These Companies

Whitehawk Therapeutics Inc WHWK

August 14 at 2:28 PM | morningstar.comM

TD Cowen Remains a Hold on Whitehawk Therapeutics (WHWK)

August 10, 2026 | theglobeandmail.com

Whitehawk Therapeutics (NASDAQ:WHWK) Upgraded by Wall Street Zen to Hold Rating

August 8, 2026 | americanbankingnews.com

Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen

August 8, 2026 | marketbeat.com

Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS

August 6, 2026 | marketbeat.com

Whitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial Cancers

August 6, 2026 | tipranks.com

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 6, 2026 | prnewswire.com

Stempoint Capital LP Sells 519,438 Shares of Whitehawk Therapeutics, Inc. $WHWK

July 30, 2026 | marketbeat.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Rating of "Moderate Buy" from Analysts

July 25, 2026 | marketbeat.com

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

July 7, 2026 | businesswire.com

10 Hot Biotech Stocks Under $5 to Buy

June 10, 2026 | insidermonkey.com

Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?

June 10, 2026 | insidermonkey.com

Whitehawk Therapeutics Presents Realâ€‘World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | gurufocus.com

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | prnewswire.com

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

May 28, 2026 | prnewswire.com

WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise

May 21, 2026 | finance.yahoo.com

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

May 21, 2026 | prnewswire.com

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

May 20, 2026 | prnewswire.com

Whitehawk Therapeutics officer Ball sells $201k in stock

May 18, 2026 | investing.com

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

May 15, 2026 | prnewswire.com

Whitehawk’s First-in-Human PTK7 ADC Trial Moves Ahead: What Investors Should Know

May 14, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INO, MRNA, TARA, and WHWK Company Descriptions

Inovio Pharmaceuticals NASDAQ:INO

$1.09 +0.19 (+21.10%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.08 -0.02 (-1.38%)

As of 08/14/2026 07:59 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Moderna NASDAQ:MRNA

$63.32 -0.33 (-0.52%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$63.21 -0.11 (-0.17%)

As of 08/14/2026 07:58 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Protara Therapeutics NASDAQ:TARA

$3.97 +0.03 (+0.76%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.98 +0.00 (+0.13%)

As of 08/14/2026 07:55 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Whitehawk Therapeutics NASDAQ:WHWK

$4.46 -0.22 (-4.70%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$4.28 -0.18 (-4.04%)

As of 08/14/2026 07:47 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INO, MRNA, TARA, and WHWK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INO, MRNA, TARA, and WHWK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INO, MRNA, TARA, and WHWK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INO, MRNA, TARA, and WHWK Company Descriptions

Inovio Pharmaceuticals NASDAQ:INO

Moderna NASDAQ:MRNA

Protara Therapeutics NASDAQ:TARA

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INO, MRNA, TARA, and WHWK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INO, MRNA, TARA, and WHWK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INO, MRNA, TARA, and WHWK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INO, MRNA, TARA, and WHWK Company Descriptions

Inovio Pharmaceuticals NASDAQ:INO

Moderna NASDAQ:MRNA

Protara Therapeutics NASDAQ:TARA

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools